Celularity (NASDAQ:CELU) Trading Up 2.4% – Here’s What Happened

Shares of Celularity, Inc. (NASDAQ:CELU) were up 2.4% on Wednesday . The company traded as high as $0.8468 and last traded at $0.8252. Approximately 275,318 shares changed hands during trading, an increase of 51% from the average daily volume of 182,465 shares. The stock had previously closed at $0.8061.

Celularity Price Performance

The firm has a market cap of $23.89 million, a PE ratio of -0.25 and a beta of 0.44. The business has a fifty day moving average price of $1.14 and a two-hundred day moving average price of $1.34.

Celularity (NASDAQ:CELU) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($0.85) earnings per share (EPS) for the quarter. The company had revenue of $4.10 million during the quarter.

Institutional Trading of Celularity

Several hedge funds and other institutional investors have recently modified their holdings of CELU. Perennial Investment Advisors LLC purchased a new stake in shares of Celularity during the third quarter worth $28,000. XTX Topco Ltd purchased a new stake in shares of Celularity during the fourth quarter worth $33,000. Acadian Asset Management LLC purchased a new stake in shares of Celularity during the first quarter worth $34,000. Jane Street Group LLC purchased a new stake in shares of Celularity during the fourth quarter worth $46,000. Finally, Bank of America Corp DE raised its holdings in shares of Celularity by 1,538.1% during the second quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock worth $73,000 after acquiring an additional 35,023 shares in the last quarter. 19.02% of the stock is currently owned by hedge funds and other institutional investors.

Celularity Company Profile

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.